Wegovy 4mg Tablets are a prescription-only oral weight management treatment containing semaglutide, a GLP-1 receptor agonist used to support weight loss in eligible adults alongside a reduced-calorie diet and increased physical activity. As part of the oral Wegovy dose-escalation programme, the 4mg strength is prescribed after the introductory 1.5mg dose to help patients gradually increase treatment while improving tolerability. For patients who prefer a tablet rather than a weekly injection, Wegovy Tablets provide a convenient once-daily alternative while using the same clinically proven active ingredient, semaglutide. Treatment should always be prescribed and monitored by a qualified healthcare professional as part of a comprehensive weight management programme.

Delivery and Returns

SKU: SK-01037 Categories: , Tags: , Brands:

Benefits

When prescribed appropriately, Wegovy may help eligible patients:

  • Reduce appetite
  • Feel fuller for longer
  • Decrease food intake
  • Support sustainable weight loss
  • Improve adherence to healthy lifestyle changes
  • Support improvements in weight-related health conditions

Results vary between individuals and treatment should always be combined with dietary and lifestyle modifications.

Features

Active Ingredient

Contains Semaglutide 4mg.

Once-Daily Oral Tablet

Simple once-daily dosing as directed by your healthcare professional.

30-Day Supply

Each pack contains 30 tablets.

Step-Up Dose

Typically prescribed following completion of the 1.5mg initiation phase as part of the recommended dose escalation schedule.

Prescription Only Medicine (POM)

Available only following an appropriate clinical assessment.

Why Choose

Wegovy Tablets provide a convenient alternative for patients who prefer oral medication over injectable treatments.

Benefits include:

  • Once-daily tablet
  • No weekly injections
  • Clinically proven active ingredient
  • Supports medically supervised weight management
  • Gradual dose escalation to improve tolerability
  • Convenient treatment option for eligible patients

Common Uses

Wegovy 4mg Tablets are prescribed for adults who meet the clinical criteria for medical weight management.

Common uses include:

Medical Weight Management

Supports adults living with obesity or overweight who meet prescribing criteria.

Appetite Control

Helps reduce hunger and increase satiety throughout the day.

Structured Weight Loss Programmes

Used alongside:

  • Reduced-calorie diet
  • Increased physical activity
  • Ongoing medical supervision

How It Works

Wegovy contains semaglutide, which mimics the naturally occurring GLP-1 hormone involved in appetite regulation.

It works by helping to:

  • Increase feelings of fullness
  • Reduce hunger
  • Slow stomach emptying
  • Support reduced calorie intake

Combined with healthy lifestyle changes, these effects can contribute to meaningful and sustainable weight management.

What is Wegovy 4mg used for?
Wegovy 4mg is used as part of the oral Wegovy dose-escalation programme to support weight management in eligible adults.
Is 4mg the starting dose?
No. Treatment usually begins with Wegovy 1.5mg, before progressing to 4mg if appropriate and well tolerated.
Do I still need to follow a healthy diet?
Yes. Wegovy is designed to be used alongside: A calorie-controlled diet Increased physical activity Long-term healthy lifestyle changes
How do I take Wegovy 4mg Tablets?
Take one tablet once daily, exactly as prescribed by your healthcare professional and according to the Patient Information Leaflet.
What are the common side effects?
Common side effects may include: Nausea Vomiting Diarrhoea Constipation Abdominal discomfort
Can I switch from Wegovy injections to tablets?
Some patients may be suitable to change formulations under medical supervision. Any changes should only be made following advice from a qualified healthcare professional.
Who can purchase Wegovy 4mg Tablets?
Wegovy is a Prescription Only Medicine (POM) and can only be supplied following a clinical assessment confirming it is safe and appropriate.